Gerd Leitinger

Prof. Dr. Gerd Leitinger

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2014 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
CSChrista Schimpel
Christa Schimpel
BTBirgit Teubl
Birgit Teubl
MAMarkus Absenger
Markus Absenger
CMClaudia Meindl
Claudia Meindl
Eleonore FröhlichEleonore Fröhlich
Eleonore Fröhlich
EREva Roblegg
Eva Roblegg

19 August 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
BGBenjamin Gottschalk
Benjamin Gottschalk
CKChristiane Klec
Christiane Klec
GLGerd Leitinger
Gerd Leitinger
EBEva Bernhart
Eva Bernhart
RRRené Rost
René Rost
Wolfgang GraierWolfgang Graier
Wolfgang Graier
Recently identified core proteins (MICU1, MCU, EMRE) forming the mitochondrial Ca2+ uniporter complex propelled investigations into its physiological workings. Here, we apply structured illumination microscopy to visualize and localize these proteins in living cells. Our data show that MICU1 localizes at the inner boundary membrane (IBM) due to electrostatic interaction of its polybasic domain. Moreover, this exclusive localization of MICU1 is important for the stability of cristae junctions (CJ), cytochrome c release and mitochondrial membrane potential. In contrast to MICU1, MCU and EMRE are homogeneously distributed at the inner mitochondrial membrane under resting conditions. However, upon Ca2+ elevation MCU and EMRE dynamically accumulate at the IBM in a MICU1-dependent manner. Eventually, our findings unveil an essential function of MICU1 in CJ stabilization and provide mechanistic insights of how sophistically MICU1 controls the MCU-Complex while maintaining the structural mitochondrial membrane framework.

28 October 2014 in Journal of Applied Toxicology
Verified
Journal Article
Closed access
PDF file
Mirta MilićMirta Milić
Mirta Milić
GLGerd Leitinger
Gerd Leitinger
IPIvan Pavičić
Ivan Pavičić
MAMaja Zebić Avdičević
Maja Zebić Avdičević
SDSlaven Dobrović
Slaven Dobrović
IVIvana Vinkovic Vrcek
Ivana Vinkovic Vrcek

1 February 2013 in Toxicology in Vitro
Verified
Journal Article
Open access
Eleonore FröhlichEleonore Fröhlich
Eleonore Fröhlich
GBGudrun Bonstingl
Gudrun Bonstingl
AHAnita Höfler
Anita Höfler
CMClaudia Meindl
Claudia Meindl
GLGerd Leitinger
Gerd Leitinger
EREva Roblegg
Eva Roblegg
Inhalation treatment with nanoparticle containing aerosols appears a promising new therapeutic option but new formulations have to be assessed for efficacy and toxicity. We evaluated the utility of a VITROCELL®6 PT-CF+PARI LC SPRINT® Baby Nebulizer (PARI BOY) system compared with a conventional MicroSprayer. A549 cells were cultured in the air-liquid interface, exposed to nanoparticle aerosols and characterized by measurement of transepithelial electrical resistance and staining for tight junction proteins. Deposition and distribution rates of polystyrene particles and of carbon nanotubes on the cells were assessed. In addition, cytotoxicity of aerosols containing polystyrene particles was compared with cytotoxicity of polystyrene particles in suspension tested in submersed cultures. Exposure by itself in both exposure systems did not damage the cells. Deposition rates of aerosolized polystyrene particles were about 700 times and that of carbon nanotubes about 4 times higher in the MicroSprayer than in the VITROCELL®6 PT-CF system. Cytotoxicity of amine-functionalized polystyrene nanoparticles was significantly higher when applied as an aerosol on cell cultured in air-liquid interface culture compared with nanoparticle suspensions tested in submersed culture. The higher cytotoxicity of aerosolized nanoparticles underscores the importance of relevant exposure systems.

9 September 2020 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
MGMichael M. Gruber
Michael M. Gruber
BHBirgit Hirschmugl
Birgit Hirschmugl
NBNatascha Berger
Natascha Berger
MHMagdalena Holter
Magdalena Holter
SRSnjezana Radulovic
Snjezana Radulovic
Christian WadsackChristian Wadsack
Christian Wadsack
Background: Nanoparticles, which are exposed to biological fluids are rapidly interacting with proteins and other biomolecules forming a corona. In addition to dimension, charge and material the distinct protein corona influences the interplay of nanoparticles with tissue barriers. In this study we were focused on the impact of in situ formed human plasma protein corona on the transfer of 80 nm polystyrene nanoparticles (PS-particles) across the human placenta. To study materno-to fetal PS transfer we used the human ex vivo placental perfusion approach, which represents an intact and physiological tissue barrier. To analyze the protein corona of PS particles we performed shotgun proteomics of isolated nanoparticles before and after tissue exposure. Results: Human plasma incubated with PS-particles of 80 nm and subsequent formed protein corona enhanced the transfer across the human placenta compared to PS-corona formed by bovine serum albumin and dextran which served as a control. Quantitative and qualitative changes of plasma proteins determined the changes in PS transfer across the barrier. Based on the analysis of the PS-proteome two candidate proteins, namely human albumin and immunoglobulin G were tested if these proteins may account for the enhanced PS-transfer across the placenta. Interestingly, the protein corona formed by human albumin significantly induced the transfer of PS-particles across the tissue compared to the formed IgG-corona. Conclusion: In total we demonstrate the PS corona dynamically and significantly evolves upon crossing the human placenta. Thus, the initial composition of PS particles in the maternal circulation is not predictive for their transfer characteristics and performance once beyond the barrier of the placenta. The precise mechanism of these effects remains to be elucidated but highlights the importance of using well designed biological models when testing nanoparticles for biomedical applications.

1 June 2013 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
BTBirgit J. Teubl
Birgit J. Teubl
MAMarkus Absenger
Markus Absenger
Eleonore FröhlichEleonore Fröhlich
Eleonore Fröhlich
GLGerd Leitinger
Gerd Leitinger
Andreas ZimmerAndreas Zimmer
Andreas Zimmer
EREva Roblegg
Eva Roblegg